Megan Dow

Throughout Megan’s career, she has focused on the nexus between science and business. As a sell-side analyst on Wall Street, Megan covered innovative biotech companies, most of whom were developing assets focused on immune regulation, and novel genetic and nucleic acid technologies.

She left banking however to take on a unique opportunity as Senior Life Science Advisor for Denmark based in NYC, where she led the U.S. investment, partnering, and engagement strategies for Danish biotech and pharma companies, and guided public engagement for key political and Royal figures pertaining to the healthcare agendas.

Megan joined Biohaven from Pfizer, where she worked in the Chief Business Office on R&D Strategy across the portfolio. An engaged member of the scientific business community, Megan is on the Steering Committee for the New York Academy of Sciences, and is a board member of the Danish American Chamber of Commerce, and she volunteers as a business and scientific strategy mentor for entrepreneurship groups. She holds her Ph.D. in Pathobiology and Immunology from New York University School of Medicine.